Center for Health Law, Policy and Practice, Beasley School of Law, Temple University, Philadelphia, PA, USA.
Women Against Abuse, Inc., Philadelphia, PA, USA.
Addiction. 2017 Dec;112(12):2206-2216. doi: 10.1111/add.13910. Epub 2017 Jul 21.
(1) To describe open source legal data sets, created for research use, that capture the key provisions of US state medical marijuana laws. The data document how state lawmakers have regulated a medicine that remains, under federal law, a Schedule I illegal drug with no legitimate medical use. (2) To demonstrate the variability that exists across states in rules governing patient access, product safety and dispensary practice.
Two legal researchers collected and coded state laws governing marijuana patients, product safety and dispensaries in effect on 1 February 2017, creating three empirical legal data sets. We used summary tables to identify the variation in specific statutory provisions specified in each state's medical marijuana law as it existed on 1 February 2017. We compared aspects of these laws to the traditional Federal approach to regulating medicine. Full data sets, codebooks and protocols are available through the Prescription Drug Abuse Policy System (http://www.pdaps.org/; Archived at http://www.webcitation.org/6qv5CZNaZ on 2 June 2017).
Twenty-eight states (including the District of Columbia) have authorized medical marijuana. Twenty-seven specify qualifying diseases, which differ across states. All states protect patient privacy; only 14 protect patients against discrimination. Eighteen states have mandatory product safety testing before any sale. While the majority have package/label regulations, states have a wide range of specific requirements. Most regulate dispensaries (25 states), with considerable variation in specific provisions such as permitted product supply sources number of dispensaries per state and restricting proximity to various types of location.
The federal ban in the United States on marijuana has resulted in a patchwork of regulatory strategies that are not uniformly consistent with the approach usually taken by the Federal government and whose effectiveness remains unknown.
(1)描述为研究目的创建的开源法律数据集,这些数据集捕获了美国州医用大麻法律的关键条款。这些数据记录了州立法者如何监管一种在联邦法律下仍然是附表 I 非法药物,没有合法医疗用途的药物。(2)展示在管理患者准入、产品安全和药房实践方面各州之间存在的差异。
两名法律研究人员收集并对截至 2017 年 2 月 1 日生效的管理大麻患者、产品安全和药房的州法律进行了编码,创建了三个实证法律数据集。我们使用摘要表来确定每个州医用大麻法中具体法规规定的变化,这些规定在 2017 年 2 月 1 日存在。我们将这些法律的各个方面与传统的联邦医学监管方法进行了比较。完整的数据集、代码本和方案可通过处方药物滥用政策系统(http://www.pdaps.org/;存档于 http://www.webcitation.org/6qv5CZNaZ 上,于 2017 年 6 月 2 日检索)获得。
28 个州(包括哥伦比亚特区)已经授权医用大麻。27 个州指定了合格疾病,各州之间存在差异。所有州都保护患者隐私;只有 14 个州保护患者免受歧视。18 个州在销售前有强制性的产品安全测试。虽然大多数州都有包装/标签法规,但各州的具体要求范围很广。大多数州都对药房进行监管(25 个州),在特定条款方面存在很大差异,例如允许的产品供应来源、每个州的药房数量以及限制接近各种类型的地点。
美国对大麻的联邦禁令导致了一系列监管策略的出现,这些策略并不完全符合联邦政府通常采取的方法,其有效性仍不清楚。